Influential Third Rock Ventures marks a decade of high-profile wins and losses with record $616M Fund IV
In the 10 years since Third Rock Ventures was founded, the VC group has been one of the industry’s most influential trendsetters in creating the past generation of biotechnology upstarts. And now it’s lined up a record $616 million for its fourth fund to begin its second decade.
The new fund bring its total take to close to $2 billion. And in this next wave founding partners Mark Levin and Kevin Starr — among the Millennium veterans who played instrumental roles early on — will be advisors only as they continue to shepherd their earlier plays. A group of 8 partners, including the newly named partner Abbie Celniker and the newly promoted Charles Homcy, will take the lead in doing the heavy lifting on company creation for Fund IV, which for Third Rock often involves an interim stint as CEO of the companies it spawns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.